Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — Investor Presentation (February 2022)
17 slides from Collegium Pharmaceutical's investor presentation, February 2022
Slide 1: Corporate Presentation
Corporate Presentation February 2022 | Nasdaq: COLL
Slide 2: Forward-Looking Statements; Non-GAAP Financial Measures
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates,"
Slide 3: Building a Leading, Diversified Specialty Pharmaceutical Company
Building a Leading, Diversified Specialty Pharmaceutical Company We are proud of the …and we are focused on building Collegium we have built… the Collegium of tomorrow A leader in Strong responsible pain financial management position Committed to Portfolio of Long-term, Significant value improving t
Slide 4: Committed to Conducting Business Responsibly
Committed to Conducting Business Responsibly Governance Act in the best interests of our stakeholders Board oversight of risk management, including ESG Environmental • • ESG strategy set by ESG Executive Steering Committee Be a responsible steward of the environment • Gender-diverse senior leadershi
Slide 5: Experienced Management Team and Board of Directors
Experienced Management Team and Board of Directors Joseph Ciaffoni Scott Dreyer Colleen Tupper Richard Malamut, M.D. President, CEO & EVP & Chief EVP & Chief Financial EVP & Chief Medical Board Member Commercial Officer Officer Officer Scott Sudduth Bart Dunn Marlo Manning Shirley Kuhlmann EVP & Hea
Slide 6: 2022: A Pivotal Year for Collegium Pharmaceutical
2022: A Pivotal Year for Collegium Pharmaceutical CRITICAL PRIORITIES XTAMPZA ER CONTRACT RENEGOTIATIONS | BUSINESS DEVELOPMENT ACQUISITIONS • Renegotiate XER Contracts • Diversify our portfolio through an (accounting for ~50% of total prescriptions) accretive commercial-stage high- synergy acquisit
Slide 7: BDSI Transaction Rationale
BDSI Transaction Rationale: Strategically and Financially Transformative • Doubles the number of commercial stage assets PORTFOLIO & FINANCIAL • Expands Collegium portfolio of differentiated pain solutions DIVERSIFICATION • Results in 2 durable growth drivers, 3 contributors to the top and bottom li
Slide 8: FY21 Financial Highlights
FY21 Financial Highlights1,2 LEVERAGED OPEX, $186.4M CASH FLAT ADJUSTED BALANCE AT YEAR-END OPEX Y/Y $50.0M DEBT $42.9M SHARES PAYDOWN REPURCHASED 1. This financial data was provided by Collegium Pharmaceutical, Inc., in its Form 10-K filed with the SEC February 24, 2022. 2. Adjusted operating expen
Slide 9: Collegium's Product Portfolio Post-Close of BDSI
Collegium’s Product Portfolio Post-Close of BDSI GROWTH DRIVERS CONTRIBUTORS LAUNCH OPPORTUNITY Note: The acquisition of BDSI has not yet closed and is subject to standard closing conditions. 9
Slide 10: Xtampza ER is Well Positioned for Growth
Xtampza ER is Well Positioned for Growth Durable asset with exclusivity through September 2033 Broad market access with strong commercial and Med D coverage Strong market position with a 33% share of the OER market1,2 Contract optimization through renegotiation of ~80% of contracts in 2022-2023 Gros
Slide 11: Nucynta Franchise is Key Contributor
Nucynta Franchise is Key Contributor Maximize profitability Four-year Commercial Runway Moderate through pricing • IP through mid-2025 prescription and contracting • Potential pediatric extension decline strategy would extend exclusivity through end of 2025 11
Slide 12: Deploying Our Cash Flows In a Systematic Manner
Deploying Our Cash Flows In a Systematic Manner • Announced high-synergy acquisition of BDSI on February 14, 2022, for ~$604 Execute M&A million, using existing cash on hand and $650M in debt1 • Cash generation provides flexibility to pursue additional business development • $100M share repurchase p
Slide 13: Business Development Focus
Business Development Focus BUSINESS DEVELOPMENT STRATEGY ANCHORED TO DIVERSIFICATION IN THREE AREAS: COMMERCIAL STAGE COMMERCIAL STAGE NON-OPIOID PAIN HIGH-SYNERGY LOWER-SYNERGY Novel non-opioid pain assets Differentiated Commercial-stage therapeutic assets Phase 2 or later assets commercial-stage p
Slide 14: The Path Forward
The Path Forward A PERIOD OF GROWTH & VALUE CREATION Financially strong organization; Total revenue growth in 2022 driven by Xtampza ER; Stable contribution from the Nucynta Franchise A FOCUSED ORGANIZATION Cost structure aligned to our strategy and going forward ambitions; Strong cash flow generati
Slide 15: Non-GAAP Reconciliations
Non-GAAP Reconciliations N
Slide 16: Reconciliation of GAAP Net Income to Adjusted EBITDA
Collegium Pharmaceutical, Inc. Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands) (unaudited) Three months ended December 31, Years ended December, 31 2021 2020 2021 2020 GAAP net (loss) income $ (25,034) $ 6,958 $ 71,517 $ 26,752 Adjustments: Interest expense 4,757 7,737 21,014 28,
Slide 17: Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses
Collegium Pharmaceutical, Inc. Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands) (unaudited) Three months ended December 31, Years ended December 31, 2021 2020 2021 2020 GAAP Operating expenses $ 32,789 29,296 132,989 123,604 Adjustments: Stock-based compensatio
Collegium Pharmaceutical — Investor Presentation (February 2022) on 6ix